A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
← catalyst calendarNCT07223190 · readout in 1,360 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
560estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-11 | estimated | When the study began enrolling |
| Primary completion | 2030-05-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-08-09 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Interventions
- Drug: Blinatumomab
- Drug: Blinatumomab
- Drug: HyperCVAD
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to 5 years from randomization
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed